Primatene Firm Expects Approval, Counts On Brand Equity, Target Market
This article was originally published in The Tan Sheet
Amphastar Pharmaceuticals expects FDA to approve an amended NDA for Primatene HFA in 2016. Executives with the firm say sales of breath-triggered Primatene HFA could exceed annual revenues from the original Primatene Mist metered-dose inhaler before it was pulled from the market in 2011.
Register for our free email digests: